Comparison of GFAP and UCH-L1 Measurements from Two Prototype Assays: The Abbott i-STAT and ARCHITECT Assays

Glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) may aid in the evaluation of traumatic brain injury (TBI). The objective this analysis was to compare GFAP UCH-L1 values measured using a handheld device compared with core laboratory platform. We analyzed plasma samples from patients TBI healthy controls enrolled Transforming Research Clinical Knowledge (TRACK-TBI) cohort study. were twice each subject prototype assays, first Abbott i-STAT™ device, second ARCHITECT® then quantified agreement biomarker obtained these two methods. 570 572 samples, respectively. by ARCHITECT platform (median 143.3 [interquartile range (IQR): 19.8–925.8] pg/mL) higher than i-STAT 116.0 [IQR: 9.2–856.5] pg/mL). platforms strongly correlated (p = 0.985). Similarly, 163.9 82.5–412.4] 122.5 63.0–297.3] 0.933). Passing-Bablok regression equations developed estimate relationship between platforms, specifically predict assays on are either be converted other.